Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
Open Access
- 6 May 2008
- journal article
- Published by Elsevier in The Breast
- Vol. 17 (5) , 506-511
- https://doi.org/10.1016/j.breast.2008.03.007
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401Journal of Clinical Oncology, 2006
- HER2and Responsiveness of Breast Cancer to Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2005
- Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast CancerJournal of Clinical Oncology, 2005
- Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based ChemotherapyOncology, 2004
- Gene copy mapping of the ERBB2/TOP2A region in breast cancerGenes, Chromosomes and Cancer, 2004
- Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene AmplificationThe Journal of Molecular Diagnostics, 2003
- Pathobiology of preoperative chemotherapyCancer, 2002
- Using HER2 to Choose Chemotherapy in Breast Cancer: Is It Ready for the Clinic?JNCI Journal of the National Cancer Institute, 1999
- The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsOncogene, 1997